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I. PURPOSE
To efficiently synthesize glycopeptides for a small cell lung cancer (SCLC) fucosyl GM-1 based vaccine construct followed by the successful conjugation of the glycopeptide to the keyhole limpet hemocyanin (KLH) carrier protein to improve the natural immune system response.
II. BACKGROUND
A new generation of vaccines is being investigated for cancer treatment. Specifically, the development of vaccine-based therapeutic anticancer strategy using carbohydrate-based antigens is of particular interest. Generating the vaccines involves utilizing complex carbohydrate epitopes as immune system markers to essentially "highlight" their over expression on cancer cells to trigger the immune system to generate the necessary antibodies to mitigate the proliferation of metastatic cells in the body. 1 However, obtaining substantial quantities of these carbohydrate structures is extremely difficult and it has become necessary to explore combining elements of "biologics" with chemistry to synthesize these compounds de novo while ensuring that the body will readily accept the synthesized antigens. 1, 2 The foundation of this generation of vaccines is the fact that a variety of protein and carbohydrate molecules that are self-antigens are expressed on surface tumor cells and may be used as targets for immune recognition and attack. To generate an effective vaccine, it is necessary to conjugate a carrier protein, like KLH, to a binding peptide (T cell activator) and a B cell epitope (B cell activator). The desired consequence is when patients are immunized in an adjuvant manner (an agent that modifies the effect of other agents while having few, if any, effects when given on its own) with synthetic carbohydrate vaccines they will be able to produce antibodies that are reactive with cancer cells. This triggers the production of antibodies that mitigate tumor spread, allowing the patient a more favorable prognosis and/or comfortable recovery. 2 Carrier proteins are essential in this process because not only are they effective immunogens, they are known to provide the MHC-II binding peptides that are bound to the epitope. It has been shown that using KLH as a carrier protein had minimal toxicity and was highly immunogenic, 3 which serves to explain why the authors began with such a carrier. Preclinical and clinical vaccination studies showed that when a variety of synthesized antigens were conjugated to KLH, an increase in IgM (antibodies that are produced immediately after exposure to an antigen) and IgG (antibody that grants immunity to a patient with regard to the specific antigen) antibody response against tumors showing the antigens was observed. 4 The vaccine detailed in this article makes use of a conjugate vaccine. A conjugate vaccine is used to create an effective immunogen by covalently attaching a poor antigen to a carrier protein to improve the immunological attributes of the antigen thereby eliciting a natural immune response in the body. Furthermore, fucosyl GM1 is heavily expressed on SCLCs while minimally expressed on normal tissues which suggest that it can serve as a highly effective marker for active immunization. 5, 6 Thus, to effectively target SCLC cells, a polyvalent Fuc-GM1 based vaccine with consistent immunogenic antigens should be investigated. 7 The KLH induces the immune response by presenting the carbohydrate to the T cells to activate them. Then, they attack the carbohydrate on the carrier protein to essentially "train" the T cells to recognize the carbohydrate as being foreign and attack it. 8 Although not a new concept, this research group aimed to enhance the immunogenicity of the vaccine by providing the MHC-II binding peptides in the environs of the epitope. The helper T cells (CD4 + T cells) bind to the antigen lying in the grove of the MHC-II binding peptide and a B cell epitope so that both B cells and T cells are activated to initiate the immune response. The cells then bind to the antigen that is presented by the carrier protein and release cytotoxic T lymphocytes (CTLs, a killer T cell) and release B cells that can then create antibodies against the antigens and eventually become memory B cells to protect the body from further occurrences of the antigen. 9
III.
SUMMARY Typical carbohydrate-based anticancer vaccines consist of a complex carbohydrate hapten (a small molecule that can elicit and immune response only when attached to a large carrier like a protein) that are overexpressed on the cancer cell, a carrier protein, and a linker that attaches the carbohydrate to the protein. This model can be seen in Figure 1 . The carrier protein is important in this process as it provides the MHC-II binding peptides bound to the epitope which aids in the presentation of the carbohydrate to the T cells for T call activation which, in turn, initiates the cellular immune response. The synthesis of such a complex molecule is as follows: To begin constructing the vaccine, Scheme 1 was followed. Fuc-GM1 hexasaccharide 2 was synthesized via a pathway not discussed in the paper. They utilized TBAF/acetic acid to deprotect the triisopropylsilyl groups and cleaved acetates, carbonate, and sialic acid methyl ester. This product was debenzylated under Birch conditions to create an acid, 3, that was then peracetylated to create a lactone. The lactone was "opened" with methanol and DMAP and acylated to create 4 (glycoside). The product was treated with Fmoc-L-allylglycine benzyl ester and Hoveyda-Grubbs catalyst (A and B, respectively) to create an olefin cross-metathesis product. The product was then subjected to catalytic hydrogenation and the side-chain olefinic linkage reduced with simultaneous selective removal of the benzyl protecting group by Fmoc-protected amine to create the cassette 5 that will then be ready for coupling. Scheme 2 results in the formation of the glycopeptide. Peptide 7 is synthesized by standard Fmoc solidphase peptide synthesis, beginning with the protected tyrosine (6) preloaded on NovaSyn TGT resin. After the resin is cleaved, peptide 7 is created resulting in 95% yield with 95% purity (confirmed by LC/MS and HNMR analysis). To create Peptide 8, peptide 7 is conjugated to the linker C 14 using standard EDCI/HOBt protocol and the Fmoc protecting group was then removed by treatment with piperdine. By attaching 8 to the carbohydrate epitope 5, glycopeptides 9 is created. Next, compound 9 is treated with piperdine/DMF and Ac 2 O/Py, consecutively. Thus the allylcarboxy protecting group is exchanged to the acetate-protected 2-sulfhydrylacetate linker by reduction using Pd(PPh 3 ) 4 /PhSiH 3 followed by acylation with SAMA-OPbf. To remove the three tertbutyl and one tert-butylcarboxy groups, 10 is treated with TFA/PhOH/H 2 O/TIPS. The compound is then treated with a degassed solution of NaOH in MeOH/H 2 O which provides 11, the desired product, in 19% yield, that can be isolated and purified by HPLC. To conjugate 11 to maleimide-activated KLH (12), 11 is pretreated with TCEP gel for 2 hours and then treated with fresh 12. The efficiency of the coupling was calculated to be 210 epitopes per molecule of KLH, an estimation born from a combination of Bradford protein assay and neuraminic acid determination according to Svennerholm.
The authors accomplished a successful de novo synthesis of the carbohydrate-based anticancer vaccine with 19% yield. In this way, they proved that chemistry can provide much flexibility in the synthesis of such "biologic" materials to compensate for the difficulty in obtaining such materials naturally.
IV. COMMENTARY
The authors were able to successfully synthesize a novel small cell lung cancer fucosyl GM1-based vaccine construct. The article, while challenging to read from the perspective of someone with little background in biological chemistry, was interesting to read and provided great insight into the amount of labor is required to synthesize such a vaccine de novo. The authors saw a fault with current biologic methodology as the materials necessary for such a synthesis are hard to come by in significant amounts. Thus, they made synthetic advancements in the area by improving the immunogenicity of current carbohydrate-based vaccines by coupling the vaccine with: a B cell epitope so that both T helper cells and B cells will be activated to regulate immune response, and placing an MHC-II binding peptide in the environs of the epitope to increase the number of epitopes presented to the T helper cells. 1 The efficient synthesis of glycopeptides for a small cell lung cancer (SCLC) fucosyl GM-1 based vaccine construct gave rise to some concerns. The reaction needed days at a time to react (up to four days) for an overall yield of 19% which I don't consider an efficient system. The vaccine that they synthesized has been made before but from a "biologics" perspective. While I understand that the authors wanted to address how the vaccine can be synthesized from readily available compounds de novo, it would have been beneficial to show results with the paper to demonstrate that these synthetically-derived vaccines are just as effective as "biologics"-based ones and are accepted in the body. 3 If the efficiency of the synthesis could be improved, I would like to see more results with a variety of carrier proteins and carbohydrates. While KLH has been shown to be effective, it is also large and bulky so a smaller carrier protein may be more efficient. Fucosyl GM1 is heavily expressed on SCLC cells but not on other cancer cells. Other possible carbohydrates to examine include 9-O-acetyl-GD3, polysialic acid and Globo H as they appear on other cancer cells and can thus be considered excellent targets for passive or active immunotherapy. 5 V.
